Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy
Abstract In the current era of available therapy for human immunodeficiency virus (HIV), life expectancy for persons living with HIV (PLWH) nears that of the general population. Atherosclerotic cardiovascular disease (ASCVD) has become a particular burden for PLWH and society at large. PLWH have historically been shown to have an excess of cardiovascular risk and subsequent events when compared to the general population. Potential explanations include the increased prevalence of traditional risk factors, direct inflammatory and immunological effects from the HIV virus itself, and metabolic adverse effects of anti-retroviral therapy (ART). Over the past few years, there has been building evidence that chronic inflammation and immune activation independent of virologic suppression contribute significantly to excess ASCVD risk. Although independent agents and combination therapies have varying metabolic effects, the evidence from major randomized controlled trials (RCTs) supports the benefits of early initiation of ART. In this review, we will discuss the epidemiology of ASCVD in HIV-infected patients compared with the general population, give an overview of potential pathogenesis of high-risk plaque in HIV-infected patients, discuss different metabolic effects of individual anti-retrovirals, and discuss the limitations in current screening models for assessing cardiovascular disease (CVD) risk and future directions for treatment..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Current HIV AIDS reports - 13(2016), 5 vom: 25. Aug., Seite 297-308 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaplan-Lewis, Emma [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Anti-retroviral therapy |
|---|
| Anmerkungen: |
© Springer Science+Business Media New York 2016 |
|---|
| doi: |
10.1007/s11904-016-0331-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2028976586 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2028976586 | ||
| 003 | DE-627 | ||
| 005 | 20230517033604.0 | ||
| 007 | tu | ||
| 008 | 200819s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11904-016-0331-y |2 doi | |
| 035 | |a (DE-627)OLC2028976586 | ||
| 035 | |a (DE-He213)s11904-016-0331-y-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Kaplan-Lewis, Emma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media New York 2016 | ||
| 520 | |a Abstract In the current era of available therapy for human immunodeficiency virus (HIV), life expectancy for persons living with HIV (PLWH) nears that of the general population. Atherosclerotic cardiovascular disease (ASCVD) has become a particular burden for PLWH and society at large. PLWH have historically been shown to have an excess of cardiovascular risk and subsequent events when compared to the general population. Potential explanations include the increased prevalence of traditional risk factors, direct inflammatory and immunological effects from the HIV virus itself, and metabolic adverse effects of anti-retroviral therapy (ART). Over the past few years, there has been building evidence that chronic inflammation and immune activation independent of virologic suppression contribute significantly to excess ASCVD risk. Although independent agents and combination therapies have varying metabolic effects, the evidence from major randomized controlled trials (RCTs) supports the benefits of early initiation of ART. In this review, we will discuss the epidemiology of ASCVD in HIV-infected patients compared with the general population, give an overview of potential pathogenesis of high-risk plaque in HIV-infected patients, discuss different metabolic effects of individual anti-retrovirals, and discuss the limitations in current screening models for assessing cardiovascular disease (CVD) risk and future directions for treatment. | ||
| 650 | 4 | |a Atherosclerotic cardiovascular disease | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Anti-retroviral therapy | |
| 650 | 4 | |a Cardiovascular risk | |
| 650 | 4 | |a Persons living with HIV | |
| 650 | 4 | |a PLWH | |
| 650 | 4 | |a Randomized controlled trials | |
| 650 | 4 | |a CVD risk | |
| 700 | 1 | |a Aberg, Judith A. |4 aut | |
| 700 | 1 | |a Lee, Mikyung |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current HIV AIDS reports |d Springer US, 2004 |g 13(2016), 5 vom: 25. Aug., Seite 297-308 |w (DE-627)390611921 |w (DE-600)2151206-1 |x 1548-3568 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2016 |g number:5 |g day:25 |g month:08 |g pages:297-308 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11904-016-0331-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2016 |e 5 |b 25 |c 08 |h 297-308 | ||